21. 11. Yu TF, Gutman AB. Principles of current management of primary gout.
Am J Med Sci 1967;254:893-907
12. Woitmann RL. Gout and Hyperuricemia. In: Gary S. Firestein RCB, Edward
D. Harris Jr., Iain B. Mclnnes, Shaun Ruddy, John S. Sergent ed. Kelly’s Textbook
of Rheumatology 8th ed. Canada: Saunders company; 2008.
13. Choi HK. A prescription for lifestyle change in patients with hyperuricemia
and gout. Curr Opin Rheumatol 2010;22:165-72.
14. Terkeltaub R. The management of gout and hyperuricemia. In: Marc C.
Hochberg AJS, Josef S. Smolen, Michael E. Weinblatt, Michael H. Weisman, ed.
Rheumatology. 5th ed. Philadelphia: Elsevier; 2010.
15. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recom-
mendations for gout. Part II: Management. Report of a task force of the EULAR
Standing Committee for International Clinical Studies Including Therapeutics
(ESCISIT). Ann Rheum Dis 2006;65:1312-24.
16. O’Sullivan JB. Gout in a New England town. A prevalence study in
Sudbury, Massachusetts. Ann Rheum Dis 1972;31:166-9.
17. Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic
criteria for gout: comparison with the gold standard of synovial fluid crystal
analysis. J Clin Rheumatol 2009;15:22-4.
18. Pelaez-Ballestas I, Hernandez Cuevas C, Burgos-Vargas R, et al. Diagnosis
of chronic gout: evaluating the american college of rheumatology proposal,
European league against rheumatism recommendations, and clinical judgment.
J Rheumatol 2010;37:1743-8.
19. Yu TF. The effect of allopurinol in primary and secondary gout. Arthritis
Rheum 1965;8:905-6.
20. McCarthy GM, Barthelemy CR, Veum JA, Wortmann RL. Influence of
antihyperuricemic therapy on the clinical and radiographic progression of
gout. Arthritis Rheum 1991;34:1489-94.
21. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of
chronic gout in patients with renal function impairment: an open, randomized,
แนวทางเวชปฏิบัติการดูแลรักษาโรคเกาต์ 21
22. actively controlled study. J Clin Rheumatol 1999;5:49-55.
22. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods,
dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:
1093-103.
23. Kullich W, Ulreich A, Klein G. [Changes in uric acid and blood lipids
in patients with asymptomatic hyperuricemia treated with diet therapy in a
rehabilitation procedure]. Rehabilitation (Stuttg) 1989;28:134-7.
24. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of
gout in men: prospective cohort study. BMJ 2008;336:309-12.
25. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake
and risk of incident gout in men: a prospective study. Lancet 2004;363:1277-81.
26. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy
products and relationship to serum levels of uric acid: the Third National Health
and Nutrition Examination Survey. Arthritis Rheum 2005;52:283-9.
27. Garrel DR, Verdy M, PetitClerc C, Martin C, Brule D, Hamet P. Milk- and
soy-protein ingestion: acute effect on serum uric acid concentration. Am J Clin
Nutr 1991;53:665-9.
28. Gao X, Curhan G, Forman JP, Ascherio A, Choi HK. Vitamin C intake and
serum uric acid concentration in men. J Rheumatol 2008;35:1853-8.
29. Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men:
a prospective study. Arch Intern Med 2009;169:502-7.
30. Huang HY, Appel LJ, Choi MJ, et al. The effects of vitamin C supple-
mentation on serum concentrations of uric acid: results of a randomized controlled
trial. Arthritis Rheum 2005;52:1843-7.
31. Baxmann AC, De OGMC, Heilberg IP. Effect of vitamin C supplements
on urinary oxalate and pH in calcium stone-forming patients. Kidney Int 2003;63:
1066-71.
32. Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate
enhances urate reduction in men treated with allopurinol for hyperuricaemia
and gout. Rheumatology (Oxford) 2003;42:321-5.
22 แนวทางเวชปฏิบัติการดูแลรักษาโรคเกาต์
23. 33. Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and
hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate)
in a double-blind, placebo-controlled trial. Metabolism 1988;37:217-20.
34. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M.
Effects of combination treatment using anti-hyperuricaemic agents with
fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62:
572-5.
35. Lyu LC, Hsu CY, Yeh CY, Lee MS, Huang SH, Chen CL. A case-control
study of the association of diet and obesity with gout in Taiwan. Am J Clin Nutr
2003;78:690-701.
36. Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-
cause and cardiovascular mortality. Rheumatology (Oxford) 2010;49:141-6.
37. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J
Med 2008;359:1811-21.
38. Nicholls A, Yablonsky H, Scott JT. Effect of weight reduction on levels
of uric acid in plasma and urine. Ann Rheum Dis 1973;32:280-1.
39. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial
effects of weight loss associated with moderate calorie/carbohydrate restriction,
and increased proportional intake of protein and unsaturated fat on serum urate
and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000;59:539-43.
40. Maclachlan MJ, Rodnan GP. Effect of food, fast and alcohol on serum
uric acid and acute attacks of gout. Am J Med 1967;42:38-57.
41. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Re R. Effect of
eprosartan and losartan on uric acid metabolism in patients with essential
hypertension. J Hypertens 1999;17:1033-9.
42. Knochel JP, Dotin LN, Hamburger RJ. Heat stress, exercise, and muscle
injury: effects on urate metabolism and renal function. Ann Intern Med 1974; 81:
321-8.
43. Bosco JS, Greenleaf JE, Kaye RL, Averkin EG. Reduction of serum uric
acid in young men during physical training. Am J Cardiol 1970;25:46-52.
แนวทางเวชปฏิบัติการดูแลรักษาโรคเกาต์ 23
24. 44. Schlesinger N. Response to application of ice may help differentiate
between gouty arthritis and other inflammatory arthritides. J Clin Rheumatol
2006;12:275-6.
45. Schlesinger N, Detry MA, Holland BK, et al. Local ice therapy during
bouts of acute gouty arthritis. J Rheumatol 2002;29:331-4.
46. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does
colchicine work? The results of the first controlled study in acute gout. Aust
N Z J Med 1987;17:301-4.
47. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment
of gout. Ann Intern Med 1966;64:229-58.
48. Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus
indomethacin in patients with acute gouty arthritis: a multicenter, double
blind comparative study. J Rheumatol 1988;15:1422-6.
49. Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE.
Randomized double-blind comparison of the analgesic efficacy of intramuscular
ketorolac and oral indomethacin in the treatment of acute gouty arthritis.
Ann Emerg Med 1995;26:682-6.
50. Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-
inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis
of randomized controlled clinical trials. Arch Intern Med 1996;156:2321-32.
51. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastro-
duodenal ulcers. Cochrane Database Syst Rev 2002:CD002296.
52. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated
with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med
2005;352:1092-102.
53. Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Systematic review and
metaanalysis of the risk of major cardiovascular events with etoricoxib therapy.
New Zealand Medical Journal 2005;118:U1684.
54. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW.
High versus low dosing of oral colchicine for early acute gout flare: Twenty-
24 แนวทางเวชปฏิบัติการดูแลรักษาโรคเกาต์
26. attacks of gout with a small dose of intraarticular triamcinolone acetonide.
J Rheumatol 1999;26:2285-6.
65. Ferraz MB, O’Brien B. A cost effectiveness analysis of urate lowering
drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995;22:908-14.
66. Gutman AB, Yu TF. Protracted uricosuric therapy in tophaceous gout.
Lancet 1957;273:1258-60.
67. Yu T, Gutman AB. Uric acid nephrolithiasis in gout. Predisposing factors.
Ann Intern Med 1967;67:1133-48.
68. Brest AN, Heider C, Mehbod H, Onesti G. Drug control of diuretic-in-
duced hyperuricemia. JAMA 1966;195:42-4.
69. Nicotero JA, Scheib ET, Martinez R, Rodnan GP, Shapiro AP. Prevention
of hyperuricemia by allopurinol in hypertensive patients treated with chlorothia-
zide. N Engl J Med 1970;282:133-5.
70. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the
relationship between serum urate level and recurrent attacks of gouty
arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic
therapy. Arthritis Rheum 2004;51:321-5.
71. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW.
Serum urate levels and gout flares: analysis from managed care data. J Clin
Rheumatol 2006;12:61-5.
72. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of
urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Arthritis Rheum 2002;47:356-60.
73. Schumacher HR. Crystal-induced arthritis: an overview. Am J Med 1996;
100:46S-52S.
74. Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate
concentrations to minimize risk of gouty attacks during anti-hyperuricemic
treatment. Adv Exp Med Biol 1998;431:13-8.
75. Scott JT, Hall AP, Grahame R. Allopurinol in treatment of gout. Br Med
J 1966;2:321-7.
26 แนวทางเวชปฏิบัติการดูแลรักษาโรคเกาต์
27. 76. Rodnan GP, Robin JA, Tolchin SF. Efficacy of single daily dose allopurinol
in gouty hyperuricemia. Adv Exp Med Biol 1974;41:571-5.
77. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description
and guidelines for prevention in patients with renal insufficiency. Am J Med
1984;76:47-56.
78. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R.
Relation between adverse events associated with allopurinol and renal function
in patients with gout. Ann Rheum Dis 2001;60:981-3.
79. Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated
with azathioprine-allopurinol interaction after heart and lung transplantation.
Transplantation 1996;61:1661-2.
80. Pak CY, Sakhaee K, Fuller C. Successful management of uric acid
nephrolithiasis with potassium citrate. Kidney Int 1986;30:422-8.
81. Trinchieri A, Esposito N, Castelnuovo C. Dissolution of radiolucent renal
stones by oral alkalinization with potassium citrate/potassium bicarbonate.
Arch Ital Urol Androl 2009;81:188-91.
82. Atsmon A, De Vries A, Lazebnik J, Salinger H. Dissolution of renal uric
acid stones by oral alkalinization and large fluid intake in a patient suffering
from gout. Am J Med 1959;27:167-71.
83. Boelaert J, Lijnen P, Robbens E, et al. Impairment of renal function due
to sulphinpyrazone after coronary artery bypass surgery: a prospective double-
blind study. J Cardiovasc Pharmacol 1986;8:386-91.
84. Walls M, Goral S, Stone W. Acute renal failure due to sulfinpyrazone.
Am J Med Sci 1998;315:319-21.
85. Florkowski CM, Ching GW, Ferner RE. Acute non-oliguric renal failure
secondary to sulphinpyrazone overdose. J Clin Pharm Ther 1992;17:71.
86. Boelaert J, Schurgers M, Daneels R, Lijnen P, Amery A. Sulfinpyrazone:
risk for renal insufficiency. Arch Intern Med 1984;144:648-9.
87. Bartels EC, Matossian GS. Gout: six-year follow-up on probenecid
(benemid) therapy. Arthritis Rheum 1959;2:193-202.
แนวทางเวชปฏิบัติการดูแลรักษาโรคเกาต์ 27
28. 88. Hahn PC, Edwards NL. Management of Hyperuricemia. In: Koopman
WJ, Moreland LW, eds. Arthritis & Allied Conditions. Fifteenth ed: Lippincott
Williams & Wilkins; 2005:2341-55.
89. Hanvivadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbro-
marone compared to allopurinol in lowering serum uric acid level in hyperuricemic
patients. J Med Assoc Thai 2002;85 Suppl 1:S40-7.
90. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled
trial on the efficacy and tolerability with dose escalation of allopurinol
300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Ann Rheum Dis 2009;68:892-7.
91. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability
of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone
versus probenecid after failure of allopurinol. Ann Rheum Dis 2009;68:51-6.
92. Zurcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbro-
marone in cyclosporin-A-treated renal transplant patients: a prospective study.
Nephrol Dial Transplant 1994;9:548-51.
93. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-
Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the
control of hyperuricaemia. A pathogenic approach to the treatment of primary
chronic gout. Ann Rheum Dis 1998;57:545-9.
94. Arai M, Yokosuka O, Fujiwara K, et al. Fulminant hepatic failure
associated with benzbromarone treatment: a case report. J Gastroenterol
Hepatol 2002;17:625-6.
95. Wagayama H, Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure
associated with benzbromarone. J Hepatol 2000;32:874.
96. Kaufmann P, Torok M, Hanni A, Roberts P, Gasser R, Krahenbuhl S.
Mechanisms of benzarone and benzbromarone-induced hepatic toxicity.
Hepatology 2005;41:925-35.
97. Takahashi H, Sato T, Shimoyama Y, et al. Potentiation of anticoagulant
effect of warfarin caused by enantioselective metabolic inhibition by the
28 แนวทางเวชปฏิบัติการดูแลรักษาโรคเกาต์